CapsoVision Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, and reaffirmed governance commitments. All proposals passed, with final results to be filed in a Form 8-K. No shareholder questions were raised.
-
Revenue remained stable at $2.8M in Q1 2026, with strong utilization and expanding clinical adoption. AI-assisted capabilities are on track for mid-year launch, and a $14M private placement bolstered the balance sheet.
-
CapsoVision highlighted its AI-powered capsule endoscopy platform, targeting major GI markets with a robust pipeline for colon, pancreas, esophagus, and stomach imaging. Strategic partnerships and recent financing support expansion and R&D through 2026.
Fiscal Year 2025
-
Revenue grew 15% year-over-year in 2025, driven by CapsoCam Plus adoption and new account growth. AI-enabled product pipeline advanced, with pivotal studies and regulatory submissions on track. Balance sheet strengthened by $14 million equity raise.
-
Q3 2025 saw 19% revenue growth, strong adoption of CapsoCam Plus, and pipeline expansion with FDA submissions for AI and pancreatic cancer screening. IPO proceeds boosted cash reserves, while a one-time R&D charge impacted net loss.
-
Q2 2025 revenue grew 17% year-over-year to $3.3M, with gross margin at 55% and net loss improving to $4.6M. Over 143,000 patients have used the capsule, and new FDA clearances plus an IPO and Canon partnership support future growth.